Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Solid Tumor: early-phase trial registry
3 of 9 indexed Malignant Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Malignant Solid Tumor: 9 US clinical trials tracked, 3 recruiting.
Malignant Solid Tumor is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is EpicentRx, running 1 of these trials.
Enrollment posture brief
Registry condition malignant-solid-tumor
OPEN 3 | RECR 33% | LATE 0 | EARLY 8 | RANK #1916 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Malignant Solid Tumor lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Solid Tumor is recruiting below its size-band peers.
3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Malignant Solid Tumor trials is spread across many organizations.
EpicentRx accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Malignant Solid Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 64 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.
-
Malignant Solid Tumor research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
NCT04145622
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ankyra Therapeutics
NCT06171750
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
NCT05468359
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT04083599
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Vanderbilt-Ingram Cancer Center
NCT03694249
Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services
University of California, San Francisco
NCT03905720
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Eli Lilly and Company
NCT01515306
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
AVEO Pharmaceuticals
NCT00725634
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
EpicentRx
NCT02518958
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Solid Tumor page
9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Malignant Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- EpicentRx sponsors the most Malignant Solid Tumor trials on record, review their full trial history before evaluating a specific study. See EpicentRx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Solid Tumor condition card totals 9 registered trials; most-linked intervention ramucirumab (IMC-1121B); top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.